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A B S T R A C T
Elevated low-density lipoprotein cholesterol (LDL-C) has traditionally been consid-
ered an independent risk factor for coronary artery disease (CAD). A level of LDL-
C< 70 mg/dl is recommended for very high risk individuals. However, it has recently 
been suggested that the threshold for atherosclerosis may be much lower and it is 
widely accepted that even with the intense use of statins, not all cardiovascular adverse 
events are prevented. Consequently, new indexes have emerged that could outperform 
LDL-C especially in the highest risk populations, such as patients with diabetes type 
II or the metabolic syndrome. Non- high density lipoprotein (HDL) cholesterol is 
defined as all of the cholesterol that is not HDL (total cholesterol- HDL cholesterol). 
It has been shown that for each LDL-C category, an increase in non-HDL cholesterol 
increased the risk for cardiovascular disease. Prospective trials have also shown that 
total apo-B level reflects the total number of apo- B lipoproteins and measures the 
total atherogenic particle number. It seems that apo-B levels are much more closely 
related to the risk of vascular events than LDL-C or non-HDL cholesterol. Finally, 
there are at least 7 distinct subclasses of LDL of different particle sizes and several 
recent studies have suggested that LDL subfraction distribution, especially the pres-
ence of increased levels of small, dense LDL particles, aid in the prediction of cardiac 
heart disease risk. Further studies will clarify the clinical circumstances that justify 
lipoprotein analysis and how to best use the information taken from these new indices 
in the management of our patients.
I N T R O D U C T I O N
Cardiovascular disease is the leading cause of death in the developed countries and 
in a few decades it will become the leading cause of death in the developing world as 
well.1 Therefore, the early identification of individuals at increased risk is of pivotal 
importance in order to modify the factors contributing to this high risk profile.
Elevated low-density lipoprotein (LDL) cholesterol (LDL-C) has traditionally 
been considered as an independent risk factor for coronary artery disease (CAD). A 
number of trials have suggested that lowering LDL-cholesterol leads to a decrease in 
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the incidence of CAD.2-5 Moreover recent randomized statin 
trials have found progressively lower risk with progressively 
lower LDL-C levels.6,7 The National Cholesterol Education 
Program (NCEP) /Adult Treatment Panel (ATP) endorses 
LDL-C as the basis for risk stratification and treatment goal.8 
A level of LDL-C< 70 mg/dl is recommended for very high 
risk individuals. However, it has recently been suggested that 
the threshold for atherosclerosis may be much lower3 and it is 
widely accepted that even with the intense use of statins in or-
der to achieve the aforementioned goals, not all cardiovascular 
adverse events are prevented.9 Consequently, researchers are 
trying to identify new indexes that would outperform LDL-
C especially in the highest risk populations such as patients 
with diabetes type II or the metabolic syndrome. Therefore, 
the role of non-HDL cholesterol, apolipoprotein B levels 
and small dense LDL particles as independent predictors of 
cardiovascular disease is currently under evaluation.
N O N -  H D L  C H O L e S T e R O L
Non-HDL cholesterol is defined as all of the cholesterol 
that is not HDL (total cholesterol- HDL cholesterol) and 
comprises the cholesterol concentration of all the apoB- 
lipoproteins, i.e. VLDL, LDL, IDL and lipoprotein(a). If 
the triglyceride level is more than 200 mg/dl, the increase of 
non- HDL cholesterol reflects the increase of triglyceride rich 
lipoproteins, i.e. VLDL. Recent data suggest that non-HDL-C 
is a good predictor of initial CAD and independent of the levels 
of LDL.11 Conducting analysis of the Framingham database, 
Liu et al. demonstrated that the risk for CAD associated with 
high non-HDL cholesterol was independent of LDL- C con-
centration. Moreover, for each LDL-C category, according to 
NCEP- ATP III, an increase in non-HDL cholesterol increased 
the risk. It seems that the combination of a high concentration 
of triglyceride- rich particles and LDL-C carries a particularly 
high risk and increasing VLDL and IDL concentrations add 
to the risk at any LDL concentration. Moreover, non-HDL-C 
has been associated with recurrent episodes of angina pectoris 
and nonfatal myocardial infarction in patients with multives-
sel CAD.12 Data from the Lipid Research Clinic Program 
cohort study13 were used to compare the predictive value of 
non-HDL-C as a risk factor for cardiovascular mortality with 
LDL-C. The follow-up period was 19 years. In men as well as 
in women, an increase in non-HDL-C level was associated with 
an increase in cardiovascular mortality and the relative risk 
was 2.14 in men with non-HDL-C >220 mg/dl compared to 
those with non-HDL-C < 160 mg/dl. In patients with hyper-
triglyceridemia or the metabolic syndrome, the NCEP- ATP 
III introduced non-HDL-C as a treatment target and many 
authors have supported the suggestion to estimate non-HDL C 
when assessing the risk in patients with low to normal LDL- C 
and treating targets are calculated by adding 30 mg/dl to the 
standard NCEP-ATP III target LDL-C.
A P O L I P O P R O T e I N  B
Each one of the atherogenic lipoproteins, i.e. each chy-
lomicron, VLDL, IDL, LDL, and lipoprotein(a) contain only 
1 molecule of apo-B. Therefore, the total apo-B level reflects 
the total number of apo- B lipoproteins and measures the 
total atherogenic particle number. Thus, in a patient with 
normal LDL-C, high apo-B levels may reflect higher number 
of small, dense, highly atherogenic LDL particles. Apo-B 
binds the atherogenic lipoproteins to proteoglycans on the 
arterial wall, thus facilitating the integration of cholesterol in 
the macrophages of the subendothelial space which transform 
into foam cells. Moreover, the oxidation of apo-B creates pro-
inflammatory products that propagate atherosclerosis in the 
arterial wall.14 Apo-B is more closely related to inflammatory 
markers than total cholesterol, LDL-C or non-HDL-C.15 This 
relation was superior to many other risk factors including body 
mass index, abdominal obesity, systolic blood pressure, fasting 
glucose, etc. Finally, the value of apo-B levels in the prediction 
of metabolic syndrome and diabetes, particularly in women 
has been shown.16 It seems that apo-B levels are much more 
closely related to the risk of vascular events than LDL-C or 
non-HDL-C as presented in many large prospective trials such 
as the AMORIS17 study, the Health Professionals Follow-up 
Study18 and the Quebec Cardiovascular Study.19 In the latter 
study, non-HDL-C was strongly correlated with apo-B across 
all cardiac heart disease categories (r=0.9) and this correla-
tion was much stronger than the correlation between LDL-C 
and apo-B, which became weaker with increasing triglyceride 
levels. Moreover, this study showed that in patients with CAD, 
both non-HDL cholesterol and apo-B levels were significantly 
elevated compared to LDL- C, so greater reduction in non- 
HDL cholesterol and apo-B than LDL-C would be required 
for optimal risk management. Finally, apo-B appears to be a 
better predictor of subsequent CAD events in patients on treat-
ment with statins.20 However, despite the clinical importance 
of apo-B levels, the cost and difficulties in the measurement 
due to lack of standardization across centers precludes its 
widespread clinical use.
S m A L L  D e N S e  L O w - D e N S I T y 
L I P O P R O T e I N
There are at least seven distinct subclasses of LDL of dif-
ferent particle sizes. Several recent studies have suggested that 
LDL subfraction distribution aids in the prediction of cardiac 
heart disease risk. The Quebec Cardiovascular Study19 con-
firmed a strong association in men of the cholesterol content 
in small dense LDL (LDLc <255Å) with the risk for ischemic 
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heart disease compared with the relationship of large LDL 
(>260 Å) to the risk that was weak. This strong association 
was independent of factors such as HDL-C, triglyceride and 
apolipoprotein B. In an analysis of subjects with the metabolic 
syndrome in the Framingham Heart Study,21 small LDL parti-
cle level was increasing with an increasing number of metabolic 
syndrome traits and those with the syndrome had higher risk 
for cardiac heart disease. Other studies have confirmed that 
subjects with increased small, dense LDL levels exhibit also 
increased VLDL, small, dense HDL and low total HDL lev-
els.22 It seems that central obesity leads to an increase content 
of fat in the liver with subsequent increased production and 
secretion of VLDL. Insulin resistance disturbs the correct 
regulation of VLDL production and low adiponectin is associ-
ated with low VLDL clearance rate. Increased VLDL levels is 
the key feature of a dyslipidemic syndrome, which initiates a 
sequence of events that generates the atherogenic small, dense 
LDL and HDL particles and it is common in diabetes, in the 
metabolic syndrome, in familial combined hyperlipidemia, in 
preeclampsia, etc.22,23 However, small, dense LDL levels failed 
to predict the onset of frank diabetes in prediabetic subjects 
whereas VLDL and small HDL concentration appeared to be 
related to future onset of diabetes.24
The role of small, dense LDL cholesterol in the pathogen-
esis and progression of the atheromatous plaque has recently 
been elucidated. Small, dense LDL is more easily oxidized and 
is subject to a higher degree of retention in the arterial wall. 
Small, dense LDL also exhibits reduced binding capacity to 
the LDL-receptor, thus is staying longer in the circulation and 
is subject to more structural changes which can increase its 
atherogenic potential. Small, dense LDL promotes endothelial 
dysfunction, inducing greater production of plasminogen ac-
tivator inhibitor (PAI)-I and thromboxane A
2
.25 Interventions 
that would modify small, dense LDL level include administra-
tion of statins that reduce all LDL subfractions, administration 
of fibrates in which case the benefits are greater in individuals 
with a predominance of small, dense LDL particles and ap-
parently peroxisome- activated receptor γ agonists seem to 
be able to alter particle size in diabetes, metabolic syndrome, 
and in hypertension without a change in plasma VLDL or 
triglyceride concentration.26
C O N C L U S I O N
Increasing number of studies are supporting the incremen-
tal value of measuring non-LDL and especially apolipoprotein-
B. Patients already on statins with high apo-B plasma level 
may still have too many small, dense LDL particles which are 
highly atherogenic and may warrant more aggressive approach 
and management may be in the form of combination of lipid- 
lowering drugs. Current guidelines clearly set LDL-C as the 
primary target of lipid lowering therapy and introduce non-
HDL as a secondary target of therapy in patients with elevated 
triglycerides level (≥200 mg/dl).8 As for the therapeutic strate-
gies, statins remain the mainstay of treatment for increased 
LDL as well as non-HDL cholesterol even as monotherapy. 
When LDL cholesterol is extremely high, a combination of 
drug therapy is advised, e.g. statins and bile acid sequestrant 
in order to reach the therapeutic goal.
Ezetimibe has complementary action to the statins adding 
an extra 20% LDL reduction and its clinical significance was 
studied in the ENHANCE trial27 that was recently published. 
The results were disappointing and raised much speculation 
since the study failed to show any benefit in the intima media 
thickness in the carotid arteries from the treatment with the 
combination of simvastatin and ezetimibe compared to simv-
astatin alone. Fibrates are considered for monotherapy only 
when triglycerides are over 500 mg/dl due to high risk of acute 
pancreatitis. However, when triglycerides fall below 500 mg/dl, 
LDL becomes again the primary target of therapy and statins 
are usually combined with a fibrate or nicotinic acid. The latter 
two drugs also increase HDL. However, ATP III does not spec-
ify a certain goal for HDL in patients with decreased levels as 
in the metabolic syndrome and outline the importance of LDL 
lowering as a primary target. Adding a drug such as a fibrate 
in a patient with low HDL after reaching LDL target may be 
considered in high risk populations. Torcertapib, a cholesteryl 
ester transfer protein (CETP) inhibitor was a promising drug 
that could substantially increase HDL cholesterol. However, a 
phase III trial, the ILLUMINATE trial,28 was terminated early 
because an interim analysis showed an increased rate of mortal-
ity in patients receiving the combination of atorvastatin and 
torcetrapib compared to those receiving atorvastatin alone.
Finally, it is very important to note that a majority of high 
risk patients even on a statin have very high levels of LDL 
cholesterol according to the ASPIRE29 and EUROASPIRE30 
registries. Therefore, all possible interventions should be 
implemented in patients according to the existing guidelines 
in order to reach the therapeutic targets and consequently 
reduce mortality and risk for cardiovascular events. Further 
large scale prospective clinical trials will clarify the clinical 
circumstances that justify further lipoprotein analysis and 
how to best use the information taken from new indices such 
as non-HDL, apolipoprotein B or small dense LDL particles, 
in the management of our patients.
R e F e R e N C e S
 1. Levenson JW, Skerrett PJ, Gazianno JM. Reducing the global bur-
den of cardiovascular disease: the role of risk factors. Prev Cardiol 
2002; 5:188-199.
 2. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent 
clinical trials for the National Cholesterol Education Program 
Adult Treatment Panel III guidelines. Circulation 2004; 110:227–
239.
66
HOSPITAL CHRONICLES 4(2), 2009
 3. O’Keefe JH Jr, Cordain L, Harris WH, et al. Optimal low-density 
lipoprotein is 50 to 70 mg/dl. Lower is better and physiologically 
normal. J Am Coll Cardiol 2004; 43:2142– 2146.
 4. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotrophic 
effects of statins: benefit beyond cholesterol reduction? A meta-
regression analysis. J Am Coll Cardiol 2005; 46:1855– 1862.
 5. Heart Protection Study Collaborative Group. MRC/BHF heart 
protection study of cholesterol lowering with simvastatin in 
20,536 high-risk individuals: a randomized placebo-controlled 
trial. Lancet 2002; 360:7–22.
 6. PROVE-IT Investigators. Intensive versus moderate lipid lower-
ing with statins after acute coronary syndromes. N Engl J Med 
2004; 350:1495–1504.
 7. REVERSAL Investigators. Effect of intensive compared with 
moderate lipid-lowering therapy on progression of coronary ath-
erosclerosis: a randomized control study. JAMA 2004; 291:1071– 
1080.
 8. Adult Treatment Panel III. Executive summary of the third re-
port of the National Cholesterol Education Program (NCEP) Ex-
pert Panel on detection, evaluation, and treatment of high blood 
cholesterol in adults. JAMA 2001; 285:2486 –2497.
 9. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorv-
astatin vs usual-dose simvastatin for secondary prevention after 
myocardial infarction. The IDEAL study: a randomized con-
trolled trial. JAMA 2005; 294:2437– 2445.
 10. Sniderman AD. Apolipoprotein B versus Non-HDL cholesterol. 
And the winner is… Circulation 2005; 112:3336-3367.
 11. Liu J, Sempos CT, Donahue RP, Dorn J, et al. Non-HDL lipo-
protein and VLDL cholesterol and their risk predictive values in 
coronary heart disease. Am J Cardiol 2006; 98:1363-1368.
 12. Bittner V, Hardison R, Kelsey SF, et al. Bypass Angioplasty Revas-
cularization Investigation (BARI). Circulation 2002; 106:2537-
2542.
 13. Ciu Y, Blumenthal RS, Flaws JA et al. Non- HDL cholesterol level 
as a predictor of cardiovascular disease mortality. Arch Intern 
Med. 2001; 161:1413-1419.
 14. Sniderman DA, Faraj M. Apolipoprotein B, apolipoprotein A-I, 
insulin resistance and the metabolic syndrome. Curr Opin Lipid 
2007; 18: 633-637.
 15. Sattar N, Williams K, Sniderman AD, et al. Comparison of the 
associations of apolipoprotein B and non-HDL cholesterol with 
other cardiovascular risk factors in patients with the metabolic 
syndrome in the Insulin Resistance Study. Circulation 2004; 108: 
2687-2693.
 16. Onat A, Can G, Hergenc G, et al. Serum apolipoprotein B pre-
dicts dyslipidaemia, metabolic syndrome and, in women, hyper-
tension and diabetes, independent of markers of central obesity-
and inflammation. Int J Obes 2007; 31: 1119-1125.
 17. Walldius G, Junger I, Holmes I, et al. High apolipoprotein B, low 
apolipoprotein A-I, and improvement in the prediction of fatal 
myocardial infarction (AMORIS study): a prospective study. 
Lancet 2001; 358: 2026-2033.
 18. Pischon T, Girman CJ, Sacks FM, et al. Non-HDL cholesterol and 
apolipoprotein-B in the prediction of coronary heart disease in 
men. Circulation 2005; 112: 3375-3383.
 19. St-Pierre A, Cantin B, Dagenais GR, et al. Low- Density lipo-
protein subfractions and the long-term risk of ischaemic heart 
disease in men. 13-year follow-up data from the Quebec Cardio-
vascular Study. Arterioscler Thromb Vasc Biol 2005; 25:553-559.
 20. Barter PJ, Ballantyne CM, Carmera R, et al. Apo-B versus cho-
lesterol in estimating cardiovascular risk and in guiding therapy: 
report of the Thirty- Person/ Ten- country Panel. J Int Med 2006; 
259: 247-258.
 21. Kathiresan S, Otvos JD, Sullivan LM, et al. Increased small low-
density lipoprotein particle number: a prominent feature of the 
metabolic syndrome in the Framingham Heart Study. Circulation 
2006; 113: 20-29.
 22. Packard CJ. Small, dense low-density lipoprotein and its role as 
an independent predictor of cardiovascular disease. Curr Opin 
Lipid 2006; 17: 412-417.
 23. Berneis KK, Krauss RM. Metabolic origins and clinical signifi-
cance of LDL heterogeneity. J Lipid Res 2002; 43:1363-1379.
 24. Festa A, Williams K, Hanley AJ, et al. Nuclear magnetic reso-
nance lipoprotein abnormalities in prediabetic subjects in the 
Insulin Resistance Atherosclerosis Study. Circulation 2005; 
111:3465-3472.
 25. Hurt-Camejo E, Camejo G, Sartipy P. Phospholipase A2 and 
small, dense low-density lipoprotein. Curr Opin Lipidol 2000; 11: 
465-471.
 26. Mudd JO, Borlaug BA, Johnston PV, et al. Beyond low- density 
lipoprotein cholesterol: defining the role of LDL heterogeneity in 
coronary artery disease. JACC 2007; 50: 1735-1741.
 27. Greenland P, Lloyd-Jones D. Critical lessons from the EN-
HANCE trial. JAMA 2008; 299:953-955.
 28. Barter PJ, Caulfield M, Eriksson M, et al; ILLUMINATE In-
vestigators. Effects of torcetrapib in patients at high risk for 
coronary events. N Engl J Med 2007; 357:2109-2122.
 29. Bowker TJ, Clayton TC, Ingham J et al. A British Cardiac Society 
of the potential for the secondary prevention of coronary disease: 
ASPIRE (Action on Secondary Prevention through Intervention 
to Reduce Events). Heart 1996; 75: 334-342.
 30. EUROASPIRE Study Group. A European Society of Cardiology 
survey of secondary prevention of coronary heart disease: princi-
pal results. Eur Heart J 1997; 18: 1569-1582.
